Hematology

At 36 months, the overall survival rate of patients with relapsed/refractory B-cell acute lymphoblastic leukemia administered brexucabtagene autoleucel was 47.1%, with a median overall survival of 26 months.

The 10 mL ready-to-administer pre-filled syringe in the first FDA-approved pre-filled syringe in this dosing size.

Altuviiio [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl; Sanofi] is high-sustained factor VIII replacement therapy indicated for routine prophylaxis and on-demand treatment to control bleeding episodes and for perioperative management in adults and children with hemophilia A.

Elranatamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody that may become the next standard of care for multiple myeloma, according to researchers.

Because of CRS and neurologic toxicity risk, the therapy is available through a REMS program.

Paroxysmal nocturnal hemoglobinuria is a rare and life-threatening blood condition.

JNJ-80202135 (nipocalimab) treats hemolytic disease of the fetus and newborn caused by maternal red blood cells.

Isatuximab and daratumumab offer promising treatment options for previously treated multiple myeloma.

Bone marrow transplant could effectively change the brain’s blood vessels from abnormally narrowing.

The trial is the first randomized phase 3 study evaluating the efficacy and safety of ciltacabtagene autoleucel patients with relapsed and lenalidomide-refractory multiple myeloma.

In her closing thoughts , Lisa Schrade, PharmD, discusses current barriers to care as well as the upcoming direction of treatment for patients with hemophilia A.

Lisa Schrade, PharmD, shares insight on the impact of inhibitors in the hemophilia A treatment landscape.

Extended half-life factor products are key contributors to successful hemophilia A treatment pathways.

Investigators emphasize the importance of a timely HLH diagnosis and prompt initiation of treatment, as well as close outpatient follow-up to increase patient survival.

Lisocabtagene maraleucel is a CD19-directed CAR T-cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.

The updated label now includes patients with cold agglutinin disease with or without a history of transfusions.

Chronochemotherapy aims to time drug delivery when the body is the least vulnerable to harmful effects, while the cancer cells are the most vulnerable.

At leukapheresis, a low frequency of differentiated CD3+CD27-CD28--T cells can indicate favorable response to CAR T-cell therapy.

Bruton’s tyrosine kinase inhibitor zanubrutinib (Brukinsa; BeiGene USA, Inc) approved for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.

Soft tissue reconstruction solutions can leverage a patient’s natural healing response.

Study data demonstrate large step forward for this patient population

A retrospective analysis presents unique results for AML treatment.

The mean annualized bleed rate was reduced by 80% from baseline and Factor VIII usage was reduced by 94% in year 3 compared to baseline.

Developments may soon impact clinical practice in hematology and oncology.

Study meets primary and key secondary endpoints, showing clinically meaningful and statistically significant improvements.